T
Tikun Olam Holdings
A leading cannabis brand and globally recognized as the pioneer of modern medical cannabis
About Tikun Olam Holdings
Tikun Olam, whose name translates to "Repair the World" in Hebrew, operates as a global medical cannabis wellness brand with a significant presence in Israel, the United States, Canada, Australia, and Europe. The company was founded in Israel by Tzahi Cohen in 2005, initially as a non-profit to supply medical cannabis to patients who had difficulty obtaining it. It began by growing a single strain under license from the Israeli Ministry of Health and distributed cannabis for free, which contributed to a grassroots movement for cannabis liberalization in Israel. In 2007, Tikun Olam received the world's first government license to operate a medical cannabis enterprise, allowing it to cultivate and dispense products directly to patients. The company became a limited liability entity in 2010.
The company's business model is vertically integrated, encompassing the entire value chain from research and development and cultivation to manufacturing and patient distribution. A core component of its strategy is a deep focus on clinical research. For over a decade, Tikun Olam has conducted numerous clinical and preclinical studies, often in collaboration with hospitals and universities, to validate the efficacy of its proprietary strains for various medical conditions. This research has resulted in one of the world's largest cannabis treatment databases, with over 30,000 patients, providing a foundation for its product development. The company generates revenue through the sale of its medical-grade cannabis products. In 2019, the Israeli operations of Tikun Olam were acquired by Cannbit Pharmaceuticals for $23 million, forming Tikun Olam-Cannbit, now a publicly traded company on the Tel Aviv Stock Exchange (TASE: TKUN).
Tikun Olam's product portfolio is built around its genetically optimized and proprietary cannabis strains, designed to provide symptomatic relief for conditions such as Crohn's disease, PTSD, cancer, and chronic pain. The product lineup is extensive, including flower, pre-rolls, vape cartridges, tinctures, topicals, and edibles. A notable achievement was the development of Avidekel, a strain with high cannabidiol (CBD) content and minimal THC, which was a significant development in non-psychoactive therapeutic cannabis. The company operates through partnerships and licensing agreements for its international expansion, such as its joint venture in the U.S. established in 2015 and a major production facility in Greece to serve the European market.
Source: Dealroom company dataNews
Open roles
Tikun Olam Holdings in the Miami ecosystem
The Tikun Olam Holdings office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tikun Olam Holdings on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tikun Olam Holdings on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


